COSCIENS Biopharma Current Valuation vs. Net Income
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.54) | Revenue Per Share | Quarterly Revenue Growth 0.176 | Return On Assets | Return On Equity |
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
COSCIENS Biopharma Net Income vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining COSCIENS Biopharma's current stock value. Our valuation model uses many indicators to compare COSCIENS Biopharma value to that of its competitors to determine the firm's financial worth. COSCIENS Biopharma is rated below average in current valuation category among its peers. It is rated third in net income category among its peers . The last year's value of Net Loss was reported at (17.61 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the COSCIENS Biopharma's earnings, one of the primary drivers of an investment's value.COSCIENS Current Valuation vs. Competition
COSCIENS Biopharma is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 472.96 Million. COSCIENS Biopharma adds roughly 1.31 Million in current valuation claiming only tiny portion of equities under Health Care industry.
COSCIENS Net Income vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
COSCIENS Biopharma |
| = | 1.31 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
COSCIENS Biopharma |
| = | (15.31 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
COSCIENS Net Income Comparison
COSCIENS Biopharma is currently under evaluation in net income category among its peers.
COSCIENS Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in COSCIENS Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, COSCIENS Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of COSCIENS Biopharma's change in net profit over the period of time. It can combine multiple indicators of COSCIENS Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -1.7 M | -1.6 M | |
| Operating Income | -23.7 M | -22.5 M | |
| Total Other Income Expense Net | 12.7 M | 13.4 M | |
| Net Loss | -17.6 M | -16.7 M | |
| Income Before Tax | -13.7 M | -13 M | |
| Income Tax Expense | 96.6 K | 101.4 K | |
| Net Interest Income | 358.8 K | 376.7 K | |
| Net Loss | -13.8 M | -13.1 M | |
| Interest Income | 507.1 K | 532.5 K | |
| Net Loss | (5.34) | (5.07) | |
| Income Quality | 1.09 | 1.15 | |
| Net Income Per E B T | 0.90 | 0.65 |
COSCIENS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on COSCIENS Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of COSCIENS Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the COSCIENS Biopharma's important profitability drivers and their relationship over time.
COSCIENS Biopharma Earnings per Share Projection vs Actual
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in COSCIENS Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Use Investing Themes to Complement your COSCIENS Biopharma position
In addition to having COSCIENS Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials ETFs Thematic Idea Now
Financials ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
To fully project COSCIENS Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of COSCIENS Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include COSCIENS Biopharma's income statement, its balance sheet, and the statement of cash flows.